세계의 2형 당뇨병 치료 시장 : 규모, 점유율, 동향 분석 보고서 - 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Type 2 Diabetes Mellitus Treatment Market Size, Share & Trends Analysis Report By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,515,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,946,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,809,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

2형 당뇨병 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 조사 보고서에 따르면 세계 2형 당뇨병 치료 시장 규모는 2030년까지 919억 달러에 달할 전망이며, 2024년부터 2030년까지의 복합 연간 성장률(CAGR)은 6.9%로 성장할 것으로 예측됩니다.

이 확대는 2형 당뇨병의 세계 부담 증가와 치료 옵션의 진보에 의해 초래됩니다. 식생활의 혼란이나 운동 부족 등 라이프 스타일의 변화가 비만율의 상승으로 이어지는 가운데, 2형 당뇨병의 이환율은 상승 경향에 있습니다. 국제당뇨병연합(IDF)에 따르면 세계 5억명 이상이 당뇨병을 앓고 있으며 그 약 90%를 2형 당뇨병이 차지하고 있습니다. 이러한 환자 수 증가는 효과적이고 혁신적인 치료에 대한 수요를 부추깁니다.

당뇨병 관리의 진보가 시장 성장을 뒷받침하고 있습니다. GLP-1 수용체 작용제나 SGLT2 억제제와 같은 새로운 유형의 치료제가 개발됨으로써 치료 성적이 대폭 향상되었습니다. 이 치료제는 혈당을 낮출뿐만 아니라 심혈관 보호 및 체중 관리와 같은 다른 혜택도 제공합니다. 지속적인 혈당 모니터와 인슐린 펌프와 같은 새로운 인슐린 제형 및 기술의 도입은 환자 관리를 더욱 향상시키고 시장 확대의 원동력이 되고 있습니다. 예를 들어, 2023년 1월, 식품의약국(FDA)은 노보 노르디스크의 당뇨병 치료제 '리베르사스'를 혈당치를 낮추는 제1선택제로 승인했습니다. 이 승인을 통해 2형 당뇨병 환자는 건강 관리 제공업체와 협력하여 치료 계획의 초기 단계에서 리베르사스를 도입할 수 있게 되며, 발병 시점부터 병리학을 관리하기 위한 새로운 옵션을 제공할 수 있습니다. 되었습니다.

또한 건강 관리 투자 증가와 당뇨병 치료에 대한 접근성 향상도 시장 성장에 기여합니다. 각국 정부와 의료기관은 당뇨병 관리 프로그램, 국민의 의식 향상 캠페인, 헬스케어 인프라의 정비에 투자하고 있습니다. 이러한 노력은 조기 진단, 치료 어드히어런스 및 전반적인 환자 관리를 강화하는 것을 목표로 합니다.

2형 당뇨병 치료 시장 보고서?하이라이트

• 2023년 2형 당뇨병 치료 시장에서는 인슐린 제제가 32.8%의 최대 매출 점유율을 차지했습니다. 이 성장은 주로 앉아있는 라이프 스타일에 의해 세계 2 형 당뇨병의 유병률이 상승하고 있기 때문입니다.
• 예측 기간 동안 2형 당뇨병 치료 시장에서 가장 높은 복합 연간 성장률(CAGR)(9.4%)을 달성할 것으로 예상되는 것은 피하 주사입니다.
• 소매 약국 부문은 2023년 2형 당뇨병 치료 시장에서 약 70.0%의 최대 판매 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 2형 당뇨병 치료 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 2형 당뇨병 치료 시장 : 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 2형 당뇨병 치료 시장 : 약제 클래스별 추정 및 동향 분석

• 세계의 2형 당뇨병 치료 시장 :약품 클래스 대시보드
• 세계의 2형 당뇨병 치료 시장 :약품 클래스의 변동 분석
• 세계의 2형 당뇨병 치료 시장 :약제 클래스별 수익
• 인슐린
• DPP-4 억제제
• GLP-1 수용체 작용제
• SGLT2 억제제
• 기타

제5장 2형 당뇨병 치료 시장 : 투여 경로별 추정 및 동향 분석

• 세계의 2형 당뇨병 치료 시장 : 투여 경로 대시보드
• 세계의 2형 당뇨병 치료 시장 : 투여 경로의 변동 분석
• 투여경로별 수익
• 경구
• 피하
• 정맥내

제6장 2형 당뇨병 치료 시장 : 유통 채널별 추정 및 동향 분석

• 세계 2형 당뇨병 치료 시장 : 유통 채널 대시보드
• 세계의 2형 당뇨병 치료 시장 : 유통 채널 변동 분석
• 유통채널별 수익
• 소매 약국
• 병원 약국
• 기타

제7장 2형 당뇨병 치료 시장 : 약제 클래스별, 투여 경를 나타낼 전망이며 유통 채널별 지역별 추정 및 동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석(2018-2030년)
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 기업/경쟁의 분류
• 벤더 상황
  • 주요 리셀러 및 채널 파트너 목록
  • 주요 기업의 시장 점유율 분석(2023년)
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • Merck &Co. Inc
  • Novartis AG
  • Novo Nordisk AS
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd

BJH

영문 목차

영문목차

Type 2 Diabetes Mellitus Treatment Market Growth & Trends:

The global type 2 diabetes mellitus treatment market size is anticipated to reach USD 91.9 billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030, according to a report by Grand View Research, Inc. This expansion is driven by the increasing global burden of type 2 diabetes and advancements in treatment options. As lifestyle changes, such as poor dietary habits and physical inactivity, contribute to higher obesity rates, the incidence of type 2 diabetes is on the rise. According to the International Diabetes Federation (IDF), over 500 million people worldwide are affected by diabetes, with Type 2 diabetes accounting for approximately 90% of these cases. This growing patient population fuels demand for effective and innovative treatments.

Advancements in diabetes management are boosting market growth. The development of new classes of medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, has significantly improved treatment outcomes. These therapies not only lower blood glucose levels but also offer additional benefits like cardiovascular protection and weight management. The introduction of novel insulin formulations and technologies, including continuous glucose monitors and insulin pumps, further enhances patient care and drives market expansion. For instance, in January 2023, the Food and Drug Administration (FDA) approved Novo Nordisk's diabetes medication, Rybelsus, as a first-line treatment for lowering blood sugar levels. With this approval, individuals with Type 2 diabetes, in collaboration with their healthcare providers, can now incorporate Rybelsus early in their treatment plan, offering a new option for managing their condition from the onset.

In addition, increasing healthcare investments and improved access to diabetes care contribute to market growth. Governments and healthcare organizations are investing in diabetes management programs, public awareness campaigns, and healthcare infrastructure improvements. These efforts aim to enhance early diagnosis, treatment adherence, and overall patient management.

Type 2 Diabetes Mellitus Treatment Market Report Highlights:

• In 2023, the insulin segment accounted for the largest revenue share of 32.8% in diabetes mellitus, type 2 treatment market. This growth primarily is attributed to the rising prevalence of type 2 diabetes around the world due to sedentary lifestyle
• Subcutaneous are anticipated to achieve the highest CAGR of 9.4% in the diabetes mellitus, type 2 treatment market during the forecast period
• The retail pharmacies segment accounted for the largest revenue share of around 70.0% in diabetes mellitus, type 2 treatment market in 2023

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. Distribution Channel
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Type 2 Diabetes Mellitus Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Diabetes
    • 3.2.1.2. Advancements In Treatment Options
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Treatment Cost
    • 3.2.2.2. Patient Non-Adherence
• 3.3. Type 2 Diabetes Mellitus Treatment Market, Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Type 2 Diabetes Mellitus Treatment Market: Drug Class Estimates & Trend Analysis

• 4.1. Global Type 2 Diabetes Mellitus Treatment Market: Drug Class Dashboard
• 4.2. Global Type 2 Diabetes Mellitus Treatment Market: Drug Class Movement Analysis
• 4.3. Global Type 2 Diabetes Mellitus Treatment Market by Drug Class, Revenue
• 4.4. Insulin
  • 4.4.1. Insulin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. DPP-4 Inhibitors
  • 4.5.1. DPP-4 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. GLP-1 Receptor Agonists
  • 4.6.1. GLP-1 Receptor Agonists market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. SGLT2 Inhibitors
  • 4.7.1. SGLT2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Type 2 Diabetes Mellitus Treatment Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global Type 2 Diabetes Mellitus Treatment Market: Route of Administration Dashboard
• 5.2. Global Type 2 Diabetes Mellitus Treatment Market: Route of Administration Movement Analysis
• 5.3. Global Type 2 Diabetes Mellitus Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Oral
  • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Subcutaneous
  • 5.5.1. Subcutaneous market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Intravenous
  • 5.6.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Type 2 Diabetes Mellitus Treatment Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Type 2 Diabetes Mellitus Treatment Market: Distribution Channel Dashboard
• 6.2. Global Type 2 Diabetes Mellitus Treatment Market: Distribution Channel Movement Analysis
• 6.3. Global Type 2 Diabetes Mellitus Treatment Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Hospital Pharmacies
  • 6.5.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Other
  • 6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Type 2 Diabetes Mellitus Treatment Market: Regional Estimates & Trend Analysis by Drug Class, Route of Administration, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. List of key distributors and channel partners
  • 8.2.2. Key company market share analysis, 2023
  • 8.2.3. AstraZeneca PLC
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Boehringer Ingelheim International GmbH
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Eli Lilly and Co.
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Merck & Co. Inc
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Novartis AG
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Novo Nordisk AS
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Sanofi SA
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Takeda Pharmaceutical Co. Ltd
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives

관련자료